Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

Since my last Eli Lilly (NYSE:LLY) (NEOE:LLY:CA) analysis, the stock has lost 12% in price.Eli Lilly stock continues to be one of the most exciting investments on the public market. With the stock ...

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also ...

Eli Lilly (NYSE: LLY) ... Now, it’s worth noting Stock Advisor ’s total average return is 988 % — a market-crushing outperformance compared to 172 % for the S&P 500.

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050. We got a glimpse into Eli ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. A new wave of value and momentum ...

Eli Lilly (LLY 1.34%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...